To the Editor:
Dr. Reichman is correct. In many countries, substandard manufacturing by unregulated pharmaceutical companies has indeed occurred, is still occurring, and no doubt will continue to occur, especially if supported by governmental officials prompted by community pride or perhaps less honorable motives. To make matters worse, for many years the only test method used to insure the therapeutic availability of a pill's ingredients was a solubility analysis, which simply measured the ability of a pill to dissolve in water.
The problem identified by Dr. Reichman is that excipients (substances added during the manufacturing process to hold the pill together), an unsuspected chemical interaction between the different medications in a combination pill, or even a poor formulation can reduce absorption through the intestinal tract. Unless adequate serum levels are achieved effectively for all ingredients, a combination pill becomes a single drug-the anathema of all effective tuberculosis treatment. In fact, studies have documented inadequate absorption rates, especially for rifampin, from such combination formulations.
Fortunately, the World Health Organization (WHO) and World Bank are fully aware of the problem and are moving aggressively to minimize the problem. At a meeting attended by all major pharmaceutical firms involved in developing combination antituberculous medications (Geneva, Switzerland; December 1994) which I chaired, there was concurrence that bioavailability studies in humans would be required before a combination product received the endorsement of WHO's Global Tuberculosis Programme. A WHO endorsement is essential if a product is to become eligible for purchase with WHO or World Bank funds.
Equally important, there was acknowledgment that only independent laboratories, located in countries other than the site of manufacturing, should be used to perform these bioavailability studies. WHO has already identified such laboratories and been in contact with them concerning bioavailability studies.
By accepting a leadership role in changing physician practices worldwide, the American College of Chest Physicians should expect that the quality of products prescribed by our members mirror the quality expected of our members. Only those products providing evidence of bioavailability in human studies should be prescribed-the same position we should take with regard to all medications produced by local or national companies-including cardiac and pulmonary drugs.
Sounds Like a PE to Me

To the Editor:
I wish to comment upon the April ACCP-SEEK Board Review Question of the Month (April 1997), 1 in which a 23-year-old woman presents with sharp left scapular pain, dyspnea, abdominal pain, and nausea. Because the patient had taken a 1,200-mile automobile ride and because the arterial blood gas revealed a pH of 7.50, Po 2 of 60 mm Hg, and Pco 2 of 30 mm Hg, we are initially encouraged to believe that this case represents pulmonary embolism (PE). However, the chest roentgenogram revealed free air under the central tendon of the diaphragm and air outlining the wall of a section of bowel. The free air suggested acute perforation of an abdominal viscus.
I am troubled by the explanation of the hypoxemia and hypocarbia, which has been attributed to "splinting and hyperventilation." Assuming the patient was breathing room air, the alveolar-arterial oxygen difference was 52 mm Hg. In this patient with presumably normal lungs, hyperventilation would lead to hypocarbia, but should not lead to severe hypoxemia. Splinting and atelectasis may result in some degree of hypoxemia, but such an abnormal alveolar-arterial difference should be accompanied by radiographically evident atelectasis. The case illustrated some very important points, but unexplained severe hypoxemia, a clear chest roentgenogram, and a 1,200-mile automobile ride should always make PE a suspect, even if (especially if) there is a concomitant intra-abdominal event.
The free air is a great finding, but I maintain that you would also have to look for PE. A better lesson would be the frequency with which PE presents as a complication of another illness. To the Editor:
The author of the question was asked to see this young woman because of the possibility of pulmonary embolism (PE). She indicated that she had been binge drinking over the entire spring break. On examination, there was rebound tenderness. Her actual blood gases were as recorded; indeed, the alveolar-arterial oxygen pressure gradient [P(A-a)O 2 ] was 52 mm Hg. A perforated duodenal ulcer was repaired and the patient recovered uneventfully.
This degree of hypoxemia, widened P(A-a)O 2 , and hypocarbia is readily explained by her pain, referred from a perforated viscus to her scapula with splinting; radiographically evident atelectasis need not be present. A normal chest radiograph is uncommon in patients with PE. 1 Chest strapping, which simulates splinting, causes nonuniformity of ventilation as measured by the single breath nitrogen test and modest intrapulmonary shunting. With a fraction of inspired oxygen of 1.0, a decrease in mean PaO 2 from 609Ϯ5.1 to 569Ϯ11.8 mm Hg has been reported. 2 It has also resulted in a decreased closing capacity from 29.7Ϯ1.1% to 24.0Ϯ3.0%. 3 Finally, in patients with strapped chests breathing air, the PaO 2 was reduced to a mean of 81 mm Hg (range, 74 to 88 mm Hg), a calculated mean P(A-a)O 2 of 24 mm Hg (range, 17 to 31 mm Hg). 4 Philosophically we apply the razor of William of Occam, who wrote, "Pluritas non est ponenda sine neccesitate" ("Entities should not be multiplied unnecessarily")-ie, the principle of parsimony or, in the modern vernacular, "keep it simple" (KIS). There can be only one answer to Board examination questions. One must choose the single best answer. The perforated viscus is a sufficient explanation of the facts in this question. It is the single best answer. 
References
Truth in Billing
Dr. Block (March 1997) 1 is to be congratulated for the standard he upholds in documenting the care of teaching patients, a standard to which all clinician-teachers ought to subscribe. Attending physicians (and I see many) who continue only to countersign their residents' notes are not only untruthful when they bill, they are also practicing inferior ICU care. To the Editor:
Gerard
Most cardiac surgical operations are performed with cardiopulmonary bypass (CPB). It has long been recognized that CPB results in abnormal hemostasis that may lead to postoperative complications. 1, 2 Several studies have shown that these patients have an intra-and postoperative activation of the fibrinolytic system, which may be one of the possible culprits of the hemostatic disorder. [3] [4] [5] [6] However, while there is a general understanding of the fibrinolytic response to CPB, little has been reported on the relationship between the type of cardiac surgical operation and the intensity of the changes observed in the fibrinolytic system. The aim of this preliminary study is to determine whether the modality of open heart surgery influences the magnitude of these changes.
We have prospectively analyzed the plasma levels of tissue-type plasminogen activator (tPA), plasminogen activator inhibitor type 1 (PAI-1), and fibrinogen and fibrin(ogen) degradation products (FDP) in 69 patients who underwent heart surgery with CPB (35 valve replacements: 19 aortic, 9 mitral, 7 both aortic and mitral; and 35 coronary bypass) and in 55 control subjects (surgery without CPB) matched for sex and age. CPB operations were all done in elective fashion and none of the patients were in congestive heart failure before surgery. Blood samples were collected three times: before surgery, and on postoperative days 1 and 7. We did not find differences in the plasma concentrations of tPA between CPB and control groups, and there were no changes in tPA levels after CPB compared with levels before surgery. However, levels of PAI-1 were significantly higher in the CPB group even before surgery (pϽ0.05) and on postoperative days 1 (pϽ0.0005) and 7 (pϽ0.005) compared with the control group. Among the subjects of the CPB group, the concentration of PAI-1 increased significantly on postoperative days 1 (pϽ0.0005) and 7 (pϽ0.005). A significant increment in fibrinogen and FDP levels was observed only on day 7 (pϽ0.01 for each). When valve replacement and coronary bypass groups were compared, the persistence of an elevated PAI-1 level on postoperative day 7 was observed only in the first group (pϽ0.025), while it returned to normal in the second (Fig 1) . Duration of surgery was similar in the valve replacement and coronary bypass groups (274Ϯ80 vs 280Ϯ109 min). The median duration of the CPB procedure was 104Ϯ52 min, and duration of ischemia ranged from 21 to 91 min. There was no association between changes in PAI-1 levels and duration of CPB or ischemia. Two patients in the CPB group and five control subjects (no statistically significant difference) developed a venous thromboembolic event in the postoperative period, but only in the CPB group was it related with a higher PAI-1 plasma concentration (pϽ0.001). These two CPB patients were in the valve replacement subgroup.
A prior study has shown that an increase in tPA during CPB (occurring intraoperatively, within the first 30 min of CPB) is associated with valve surgery to a greater extent than coronary artery bypass grafting. 6 We have not measured fibrinolytic parameters during surgical intervention. However, our study demonstrated that the postoperative increase in PAI-1 is more durable in patients who undergo valve replacement than in those undergoing coronary bypass. Biologic mechanisms that would explain this difference are unclear to us; perhaps more intense endothelial damage occurs secondary to surgical technique in valve replacements. On the other hand, elevated PAI-1 levels postoperatively are associated with an increased risk of venous thromboembolism; 7 curiously, in our study, those patients in the CPB group who had a thromboembolic event in the postoperative period had a significantly higher PAI-1 plasma concentration. In conclusion, it seems that the valve replacement modality of cardiac surgery is associated with more durable changes in the fibrinolytic system than the coronary bypass modality, and this contingency may have clinical consequences. Certainly, further studies are needed to elucidate the mechanism and the clinical significance of these findings. The Case for Troponin T
To the Editor:
In the January 1997 issue of CHEST, Brown and Bertolet 1 make a compelling argument for the use of troponin rather than creatine kinase (CK) as the marker of choice for detecting myocardial injury. I agree, but I must differ with several issues leading them to conclude that troponin I is more sensitive than troponin T. Specifically, Brown and Bertolet state that there has been no head-to-head comparison of the two troponins, and that troponin T is inappropriately elevated in patients with end-stage renal disease who show no signs of myocardial disease. 1 Recently, two reports have been published refuting their argumentspossibly the authors were not aware of these reports when writing their article. Ohman et al 2 did compare troponin T to troponin I as predictors of adverse cardiac events in more than 600 patients with the acute coronary syndrome. Using receiver-operator curves and a multiple regression model, they concluded that troponin T had a greater sensitivity than troponin I in detecting patients who would eventually have a myocardial infarction and/or die within 30 days. Furthermore, the concern that troponin T is inappropriately elevated in patients with renal failure has been clarified and rejected in an abstract by Haller et al. 3 They assessed the cardiac troponin T levels in 97 patients with renal failure and classified them into three groups: 22 with coronary artery disease proved by angiography or prior myocardial infarction, 40 with two or more recognized risk factors, and 28 with no risk factors. In each, the troponin T value was correlated with cardiac risk; meanϮSD values were 0.26Ϯ0.08 ng/mL, 0.23Ϯ0.06 ng/mL, and 0.07Ϯ0.02 ng/mL for the three groups, respectively. Increased troponin T in patients with renal disease was a function of severity of cardiac risk and most likely indicated minimal cardiac injury in this patient population.
Another benefit of troponin T that has not been discussed is the low clinical cutoff (0.1 ng/mL) of troponin T assays, allowing detection of even minor infarcts. Cutoffs for troponin I assays vary by manufacturer and are often too high to detect microinfarcts, and lower cutoffs can result in false positives. According to Ohman et al, 4 troponin T has been shown to be an excellent prognostic indicator of adverse cardiac events in patients with unstable angina, due to its analytical sensitivity at very low concentrations.
Bernard E. Statland, MD, PhD Vanderbilt University Medical School
Nashville, Tennessee To the Editor:
We thank Dr. Statland for his comments. We have examined the abstract by Haller et al. 1 According to the standardized troponin T test, each group had elevated levels of troponin T. However, according to a new more specific enzyme-linked immunosorbent assay (ELISA), patients with proven coronary artery disease (CAD) and patients with two or more cardiac risk factors but without CAD had elevated levels. Therefore, in patients with and without CAD and chronic renal failure, cardiac troponin T is unable to distinguish patients with acute myocyte injury, which is the purpose of the test.
In the abstract by Ohman et al, 2 both cardiac troponins T and I were helpful in stratifying patients with acute coronary syndromes by risk. In order to make further comments regarding the comparison of troponins I and T performed by these investigators, we will wait for peer review and publication of the data.
Regardless, these and other emerging articles support the use of cardiac troponins as more sensitive and specific tools/markers for acute myocyte injury than creatine kinase (CK) or CK-MB. 
Cardiac Troponins in the Diagnosis of Myocardial Contusion An Emerging Controversy
I am writing in response to the excellent study and presentation entitled "Circulating Cardiac Troponin T in Myocardial Contusion," by Ferjani et al (February 1997) . 1 In spite of their well-defined attempts in the methods of selection and their exemplary efforts in the hemodynamic control of the 29 patients diagnosed as having myocardial contusion, I feel that certain comments and questions are in order. Even though the study appears to be statistically overburdened for the small number of patients presented, the results of the cardiac troponin T (cTnT) assays seem to be in general agreement with the sensitivity and specificity of others, 2 although to my knowledge, all studies to date are limited in design and by the small numbers of patients available.
The receiver operating characteristic (ROC) curves and associated areas under them were beautifully done, but I feel the reader would have been better served by a master table indicating each patient's cardiac diagnosis and abnormality, extent of trauma, results of the enzyme analysis, hemodynamic parameters, etc, so that a more reasonable evaluation of the conclusions reached by the authors could be ascertained.
I would also question the authors' use of 0.5 g/L as the clinical cutoff for the cTnT analysis, when the normal reference range is Ͻ0.1 g/L. Mair et al 3 have reported positive cTnT values of Ͼ1.0 g/L in 64% of patients with myocardial contusion, in contrast to the 31% of Ferjani et al, who used one half the assay cutoff point. Furthermore, Mair et al 4 reported increases of cTnT in 72% of patients with suspected myocardial injury and peak levels of 0.6 to 5.1 g/L. It should also be noted that the authors did not use the more well-defined CK-MB(MASS) determination in their analysis of this enzyme. Would this have made a difference in their statistical analysis?
More importantly, I would question the use of the troponin T enzyme-linked immunosorbent assay (ELISA) measurement rather than the more updated, recent versions of this assay. It has been well documented that the original ELISA test has exhibited analytic and biological nonspecificity. 5 The ROC curve from the article by Ferjani et al 1 (shown in Figure 1 ) suggests that a lower cutoff may be more appropriate. Would this have altered the sensitivity and specificity calculations to a noticeable degree? The cardiac markers were performed serially on admission, and at 4 and 24 h thereafter. Which measurement did the authors utilize in the calculation of their data analysis-the admission or the peak value? Also, a 48-h measurement of cTnT would have been most welcome.
I am also concerned over the fact that the principal mode of diagnosis for myocardial contusion was that of echocardiography (26 of 29 patients). The authors noted septal abnormalities in 19 of these patients, without individually comparing their additional abnormalities to the type and extent of the traumas they sustained. Nine patients were listed as having cardiac complications, including seven with severe cardiac arrhythmia, one with severe conduction defect, and one with hemopericardium. Were these the same nine patients identified by the cTnT value of 0.5 g/L? It would also be of value to the reader to know how well the presence of (or, in fact, the magnitude of) cTnT Ͼ0.5 g/L correlated with the severity of the cardiac complications.
The criterion utilized in making the diagnosis of myocardial contusion was one (or more) of the following: (1) abnormal echocardiogram; (2) severe cardiac rhythm disturbance; (3) severe cardiac conduction abnormality; and (4) hemopericardium. Which patients had any number of the above? This is where a master table would have been of immense value. Even though the sensitivity and specificity of ST-segment and T-wave abnormalities are admittedly limited and their presence may be greatly influenced by the hemodynamic and neurohumoral mechanisms involved in severe trauma, their omission, especially peaked T-waves or ischemic-type ST-T changes, could affect the outcome of the study and possibly influence its results.
The molecular weight of creatine kinase is listed as being 86,000 d, troponin T as 37,000 to 39,700 d, troponin I 21,000 to 24,000 d, and myoglobin 17,800 d. The peak release of cTnT can vary from 23 to 96 h. Therefore, the release kinetics of the various enzymes can differ, and have been studied predominantly in more extensive fashion in patients with myocardial ischemic disorders whose enzyme levels are much higher than those found in patients with myocardial contusion.
Severe abdominal and lower extremity crush injuries are known to transmit sufficient hydrostatic pressure (force) to the heart by way of the great vessels, thereby increasing the pressure within the heart to such an extent that internal (subendocardial) myocardial contusion can result, as can minute lacerations, valve disruption, or myocardial rupture. One cannot determine from this study the various interactions of the trauma sustained with the pathology involved and the conclusions rendered.
The work of Adams et al 6, 7 suggests that the measurement of cardiac troponin I (cTnI) accurately detects cardiac injury in patients with blunt chest trauma and should facilitate the diagnosis and management of such patients.
There is universal agreement that the lack of definitive criteria for the diagnosis of myocardial contusion has thwarted our efforts to select risk factors for the prediction of complications among patients in the various stages and subsets of blunt cardiac injury, as well as in our attempts at prognostication. Both cTnT and cTnI have high specificities for the detection of myocardial injury, certainly more so than CK-MB of any form. It is the sensitivity of each that is in question, especially in reference to myocardial contusions.
All criteria to date, as utilized for the diagnosis of myocardial contusion, have their proponents and adversaries. The ECG, the monitored ECG, technetium-labeled pyrophosphate scanning, thallium single photon emission computed tomography scintigraphy, radionuclide angiography, and echocardiography have all been discussed controversially in the medical literature. Since I believe that it is just as important to exclude the diagnosis of myocardial contusion as it is to make this diagnosis in properly selected patients, I feel it is necessary and appropriate that a chest radiograph, serial electrocardiogram, cardiac enzyme tests, and echocardiography be performed in these patients. This basic observation is almost mandatory from a medical/legal standpoint, as I previously have stated. 8 It must be emphasized that a high index of suspicion and sound clinical judgment are equally necessary in the diagnosis and management of these patients.
Ferjani et al 1 are to be complimented on their fine addition to the badly needed knowledge on a very difficult and controversial subject. Unfortunately, the absence of the use of cTnI in the comparative enzyme analysis of these patients detracted from its value, as this would have shed additional light on the matter in question. Perhaps after all is said and done, especially with reference to myocardial contusion, the "I's" have it. Only time (and further studies) will tell. 
To the Editor:
We thank Dr. RuDusky for his comments regarding our paper (February 1997) 1 and would like to offer the following responses: First, as suggested by Dr. RuDusky, Table 1 depicts the most important parameters in the 29 patients who sustained myocardial contusion. Unfortunately, it was not possible to correlate troponin levels with the magnitude of cardiac complications. We must add that the maximum values of troponin T over the first 24 h were considered in our study.
Second, Dr. RuDusky suggests that a different cutoff value for troponin T could improve its performance as a diagnostic indicator. This is precisely why we used ROC curves, which are independent of the cutoff value chosen. Obviously, the ROC curve demonstrates that changing the cutoff value is not the solution to the problem.
Third, Dr. RuDusky suggests that ST-T segment and T-wave analysis could have affected the outcome of the study. We agree with this comment, but we think that this analysis is not reliable in severe trauma patients.
Fourth, Dr. RuDusky indicates that it is also important to be able to rule out the diagnosis of myocardial contusion, even if a test has a low sensitivity. We agree with this comment, but our study does not support this possibility. Indeed, because of the low sensitivity of troponin T, our study suggests that it is not possible to accurately rule out the diagnosis of myocardial contusion. In contrast, because of its relatively high specificity, an elevated troponin T value may be of some importance in suspecting myocardial contusion.
Fifth, Dr. RuDusky suggests that troponin I could be more useful than troponin T in the diagnosis of myocardial contusion. Since we did not measure it, we are unable to verify this point. Nevertheless, it should be pointed out that the sensitivity of troponin T was only 0.35. Thus, even if troponin I slightly increases this sensitivity, we are afraid that the improvement would not be of great enough magnitude to modify anything. This is the reason why, in the conclusion of our paper, we presented our concern for the unlikeliness of any biological diagnosis of myocardial contusion in the future. We would be happy to hear that our prediction is wrong. 
Mustapha Ferjani, MD
Cytomegalovirus as a Pulmonary Pathogen
I read with interest the article "Cytomegalovirus as a Primary Pulmonary Pathogen in AIDS" by Waxman and colleagues (January 1997). 1 They reported that in some patients with AIDS, cytomegalovirus (CMV) represented a primary pulmonary pathogen. They also recommended that clinicians consider the diagnosis and the treatment with anti-CMV therapy. However, their findings didn't completely establish an etiologic role of CMV as a primary pulmonary pathogen.
Generally, CMV infections are effectively controlled by the immune system without the ultimate clearance of the virus. It was reported that CMV evolved a unique mechanism for selectively limiting the presentation of the potentially immunogenic immediate-early (IE) protein, which might preclude IE-specific cytotoxic CD8ϩ lymphocytes from providing protective immunity to CMV infection. 2 von Laer et al 3 suggested that during viremia, leukocyte populations could be infected with CMV and that polymorphonuclear leukocytes were a major target cell during active infection.
Waxman et al 1 defined CMV pneumonitis as the universal presence of the following criteria: (1) positive CMV cultures from both BAL and transbronchial biopsy (TBB) specimens; (2) characteristic cytomegalic inclusion bodies from both BAL and TBB specimens; and (3) absence of any other pulmonary pathogen. However, as they reported, pulmonary CMV disease still remains a confusing disease in patients with AIDS because there are no definite criteria for diagnosis of the disease, and the number of CMV-specific inclusions on histologic study appears unrelated to clinical manifestations. 4 A large prospective study is necessary to evaluate the diagnostic role of the criteria for CMV pneumonitis. It is also unknown how Waxman et al 1 proved the absence of other viral infections.
The diagnosis of active CMV infection can be also established by isolating the virus from clinical specimens. Although the appearance of characteristic cytomegalic inclusion bodies is specific for CMV infection, generally it is very hard to detect from clinical specimens. Polymerase chain reaction (PCR) and other molecular biological assays for CMV provided a rapid, sensitive, and specific method to diagnose active CMV infection as viral DNA is present in the clinical specimens such as serum or BAL of patients infected with CMV. 5 More sensitive and specific methods of diagnosis for active CMV infection may allow prospective longitudinal study.
Kei Numazaki, MD, PhD Department of Pediatrics Sapporo Medical University School of Medicine
Sapporo, Japan To the Editor:
We appreciate the opportunity to address the questions raised by Dr. Numazaki. He points out that we did not completely establish the etiologic role of cytomegalovirus (CMV) in these nine cases of pneumonitis. 1 We absolutely agree and point out that the retrospective nature of the study design does not allow for causality to be examined. In fact, one of the study objectives was to develop explicit criteria using information that would be available to most clinicians for this "clinical diagnosis," so that it will be more feasible to collect prospective data. We agree that the establishment of diagnostic criteria for CMV pneumonitis in human immunodeficiency virus (HIV) infection represents a challenging task. However, we would claim that the strict criteria we used, ". . . the universal presence of: (1) positive CMV cultures from both BAL and transbronchial biopsy specimens; (2) cytological examination that documents the typical cytopathologic condition of CMV with characteristic enlarged cells with large pleomorphic nuclei and intranuclear and cytoplasmic inclusions; and (3) absence of any other pulmonary pathogen . . . in the clinical setting of dyspnea, hypoxemia, and interstitial infiltrates," 1 distinguishes our study from previous studies, and represents the most rigorous approach to describing this clinical entity, within the limitations of available data.
Because CMV is frequently isolated from respiratory secretions of AIDS patients and is often found along with other pathogens such as Pneumocystis carinii, 2 diagnosis is difficult. Moreover, without cytopathologic changes it is unclear if CMV represents a pathogen. 3 All of our patients had cytopathologic changes documented, absence of any other pathogen documented, and the clinical criteria noted above. As detailed in our methods, all samples were cultured for all viral pathogens, not just CMV. We do agree, as we stated in our discussion, that to address more adequately causality, diagnosis, and outcome, a large prospective study is required.
Finally, Dr. Numazaki makes the point that the diagnosis of CMV infection can be established by isolating the virus from clinical specimens. We would argue that if the diagnosis of pneumonitis is being considered, that approach is not adequate. In bone marrow transplantation the culture of CMV from BAL fluid is fairly reliable in identifying infection. 4 This has not been the case in HIV-infected patients in whom recovery of virus without cytopathologic evidence of invasion does not necessarily represent disease. 5 He suggests polymerase chain reaction (PCR) as a more rapid, sensitive, and specific diagnostic test. Although PCR data were not available for our patients, we would argue that the specificity of PCR for clinical CMV pneumonitis might potentially be low. As mentioned above, CMV is frequently isolated from patients who do not have active pulmonary disease. The benefits of a very sensitive test would need to be weighed relative to the consequences of more false-positives resulting from the unavoidable tradeoff of lower specificity. Furthermore, it is unclear that we even know what the operating characteristics of PCR are for CMV pneumonitis. While the use of PCR has been studied in AIDS patients with retinitis 6 and CNS disease, 7 it has not been studied in patients with pulmonary disease. We suggest that the use of our diagnostic criteria may also help to prospectively study the performance of PCR and other diagnostic tests.
Community-Acquired Pneumonia Need for a Cost-Effective Approach to Treatment
To the Editor:
Patients with mild community-acquired pneumonia (CAP) can be treated as outpatients, but more severe cases of pneumonia require inpatient treatment with parenteral antibiotics. Siegel and colleagues (October 1996) 1 demonstrate the usefulness of short-term parenteral therapy, which would help reduce the period of hospitalization and cost of therapy for these patients. This need to cut costs is even more relevant in developing countries. Emergence of drug-resistant bacteria results in an additional financial burden. 2, 3 In countries like India, second-and third-generation antibiotics are unaffordable to a large number of patients attending state hospitals.
We conducted a study of patients admitted to a community-based hospital in Bombay to assess, in particular, the effectiveness of penicillin and ampicillin in the treatment of inpatients with moderate to severe CAP. There were 20 patients, 15 male and 5 female, between 15 and 71 years of age. Immunocompromised, chronically debilitated, or otherwise bedridden patients were not included.
Four patients were chronic smokers, one was a diabetic, and seven (six receiving ampicillin and one receiving penicillin) were significantly undernourished. None had radiologic evidence of interstitial pneumonia, probably because most such patients are treated as outpatients. Patients were started randomly receiving either parenteral penicillin (1 million units IV every 6 h) or ampicillin (500 mg IV every 6 h), and on discharge they continued receiving oral antibiotics, with a total therapy duration of 10 days. Apart from routine blood and radiologic studies, special care was taken to identify any tubercle bacilli in the sputum.
Fourteen patients received ampicillin and six received penicillin. Five who received ampicillin and one who received penicillin had extensive pneumonia (more than one lung zone involved or bilateral involvement). The sputum of one patient showed acid-fast bacilli, and antituberculous drugs were started. Response to treatment was good in all the other patients. All of them became afebrile by the fourth day, and none of the patients developed any of the complications of pneumonia. The mean hospital stays in the ampicillin and penicillin groups were 5.6 and 6.0 days, respectively.
A much more comprehensive study is necessary, including isolation of causative organisms and their drug sensitivities. However, this study does indicate that in the study population, most patients with CAP and radiologic features of lobar or bronchopneumonia who require hospitalization can be treated safely with parenteral ampicillin or penicillin, irrespective of the extent of the pneumonia and underlying nutritional status. Ampicillin has the advantage of resulting in a marginally shorter hospital stay. A tuberculous etiology needs to be excluded, and bedridden, chronically debilitated, and immunocompromised patients are likely to require a broader antibiotic course. On the basis of a small study of their own patients, Dr. Prabhudesai and colleagues have determined that their patients who develop community-acquired pneumonia (CAP) and have only mild comorbidities can be treated with parenteral and later oral penicillin or ampicillin. This is a reasonable approach in countries in which more expensive antibiotics are "unaffordable." For patients from whom a good quality sputum sample can be obtained, one might use a Gram's stain to decide whether ampicillin is the more appropriate antibiotic choice for a particular patient, when Gram-negative bacilli are detected on smear.
An empiric trial of treatment with penicillin or ampicillin is possible, provided that patients are carefully observed for clinical deterioration and continued signs of infection. Prabhudesai and colleagues observed, as we have in our series, 1 that patients with CAP generally respond quickly to therapy; if patients do not have a reduction of their fever in 48 h, I would suggest that antibiotic coverage be broadened to include aerobic Gram-negative bacilli and possibly the atypical sources of infection (Mycoplasma, Chlamydia, and Legionella).
Streptococcus pneumoniae is the most common organism in any group of patients with CAP, 2 and both penicillin and ampicillin provide adequate antibacterial coverage of this organism. Studies of CAP have shown that even in patients infected with S pneumoniae of intermediate penicillin resistance, there is the same response to routine therapy as in those infected with a penicillin-sensitive S pneumoniae. 3 Dr. Prabhudesai and colleagues have pointed out that one must be aware of the organisms and microbial sensitivities present in the community in which one practices. They appropriately screen all of their patients for Mycobacterium tuberculosis, as they practice in a community with a high incidence of this infection. Knowledge of the infecting organisms and bacterial sensitivities in the local community permits one to prescribe the most appropriate antibiotics for an individual patient, decrease the development of antibiotic resistance, and save scarce medical resources as well. 
Anti-inflammatory Effect of Suplatast Tosilate on Mild Asthma
Inhaled corticosteroids are generally recognized as effective in the suppression of eosinophil proliferation and migration into the bronchial mucosal of asthmatics. 1 Suplatast tosilate (IPD; Taiho; Tokyo, Japan) is a novel capsular antiasthmatic drug that suppresses both IgE production and eosinophil infiltration through selective inhibition of interleukin (IL)-4 and IL-5 synthesis by helper T cells. 2 The clinical and anti-inflammatory effects of IPD were assessed by symptom score, provocative concentration of histamine causing a 20% fall in FEV 1 , (PC 20 -histamine), induced sputum, and bronchial biopsy before and after 6 weeks of treatment with IPD capsules (300 mg/d tid or 400 mg/d bid) in patients with mild asthma. Eleven randomly selected patients aged 36 to 68 years (mean, 47.3 years) were treated with mild bronchodilators alone. The study protocol was approved by the Ethics Committee of Doai Memorial Hospital, and all subjects gave written informed consent. PC 20 -histamine was measured by the tidal breathing method after withdrawal of medications for at least 12 h. Sputum was collected by stepwise inhalation challenge with hypertonic saline (3 to 5%). Bronchial biopsy specimens were obtained from several bifurcations in eight patients by fiberoptic bronchoscopy. Bronchial mucosal tissues and induced sputum were stained with hematoxylin-eosin and with a monoclonal antibody against eosinophil cationic protein (anti-EG 2 ; Pharmacia; Uppsala, Sweden) for immunohistochemical evaluation. Stained mucosal cells were counted according to the method of Moqbel et al, 3 and such cells in the sputum were also counted and expressed as a percentage of 500 cells.
As shown in Table 1 , IPD caused a significant improvement in the PC 20 -histamine value, a significant reduction in the percentage of eosinophils in induced sputum, and a significant reduction in the number of eosinophils and EG 2 -positive cells in the bronchial mucosal tissues. Hematoxylin-eosin-stained bronchial mucosal tissues showed a clear reduction in mucosal eosinophil infiltration after IPD administration.
An ongoing airway mucosal inflammatory process has been demonstrated in patients with mild or asymptomatic asthma, characterized by eosinophilic and lymphocytic infiltrates, secondary epithelial injury, and subepithelial fibrosis. 4 The considerable eosinophil infiltration in the airway of patients with mild asthma observed in the recent study suggests the necessity of inhibiting eosinophil infiltration even in patients with mild asthma.
In summary, asthmatic patients treated with IPD showed parallel changes in inhibition of eosinophil infiltration and improvement in bronchial hyperresponsiveness, suggesting that IPD may be as useful to treat mild bronchial asthma as inhaled corticosteroids.
Cigarette Smoking Habits Among Primary School Children in Turkey
We read with great interest the article by Meijer and colleagues (October 1996). 1 Turkey is a developing country with an estimated population of 62,526,000 in 1995, of which 40,664, 276 were Ͼ15 years of age. This population, which is predominantly young and has a high fertility rate, is expected to reach 67 million by the year 2000. Smoking prevalence among the adult population (Ͼ15 years of age) is higher than the average prevalence of both the developing and the developed countries, with figures in the general population of 62.8% in men and 24.8% in women. 2 According to the World Health Organization, Turkey ranks sixth in the world in cigarette consumption and, despite these high figures, per capita consumption of manufactured cigarettes shows an average annual increase of 1% between 1990 and 1995 (from 77,314 metric tons to 93,000 metric tons). 3 This trend can be attributed to the invalidation of Turkish National Monopoly in 1986 and to the liberalization of tobacco manufacturing and trading in 1991. Also, the introduction of two large multinational companies, Philip Morris and Reynolds Tobacco International, into the Turkish tobacco market increased the market share five times between the years 1984 and 1994. These changes in tobacco policy and the volume of advertising by transnational companies (which accounted for 14.5 million US dollars in 1996) led to consumers preferring foreign tobacco blends in Turkey. 4 Until November 1996, there had been no legislation to intervene in the overwhelming smoking epidemic in Turkey. To expose the threats of all these factors toward cigarette smoking in the youth of Turkey, we studied primary school children in 1996 prior to institution of the law, "The Prevention of the Harms of Tobacco Products Law (No: 4207)."
In this cross-sectional study, a self-completed questionnaire was given to all students in grades 2 through 5 (ages 7 to 13 years) in three selected primary schools, each representing one of the three socioeconomic classes (high, middle, and low income) as reflected by the districts in Ankara. The questionnaire included multiple choice questions related to the student's age, gender, smoking status, purchasing of cigarettes in the last week, and knowledge and attitude toward the smoking habits of parents, teachers, and the public. The child's smoking status was determined by one of four possible answers, as in a previous study: 5 (1) never smoked; (2) tried smoking once or a few times; (3) smoked sometimes, less than one cigarette a week; (4) smokes more than one cigarette a week. Smoking status was defined as never smoker (answer 1) and ever smoker (answer 2, 3, or 4). The students also were requested to write either "yes" or "no" in the blank beside each disease in a list (lung cancer, cough and sputum expectoration, heart attack, vessel diseases, stomach ulcer, and stroke) to determine their beliefs in a causal relationship between tobacco use and these diseases.
Of the 1093 students, 1031 (94.4%) answered the questionnaire (55% male). The prevalence of ever smokers was 11.7% (14% among boys and 9% among girls) ( 2 ϭ5.76, pϽ.05). The highest ever smoker rate was obtained in children aged Յ8 years (19.6%, 2 ϭ14.5, pϽ.002). The prevalence of ever smokers was not significantly different between schools by districts ( 2 ϭ2.69, pϾ.05). Either one or both parents of 710 of 1080 children (65.7%) were smokers. The prevalence of ever smokers was significantly higher among children whose parents smoke than those with nonsmoking parents (4.8% vs 15.3%, 2 ϭ24.67, pϽ.001). Among the subjects, 23.6% reported purchasing cigarettes within the last week. Most children (81.2%) stated that smoking should be prohibited in public places, without a significant difference based on their smoking habits. Of the 118 ever smokers, 89 (75.4%) were against their parents' smoking. Most children (68.6%) stated that they had not been taught about the adverse health effects of smoking by their teachers. Lung cancer was most commonly identified as a smokingrelated disease (43% of the students); the least identified disease was stroke, with a rate of 4.5%. Our figures show a high ever-smoking prevalence among children aged 8 to 11 years in one city in Turkey. We agree with Meijer and colleagues that smoking prevention programs should be started in the first grades of elementary school. The antismoking race has begun in Turkey, and there is much to do, for which further studies shall be needed.
